New York State Teachers Retirement System held its position in Anika Therapeutics Inc (NASDAQ:ANIK) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 14,566 shares of the biotechnology company’s stock at the end of the first quarter. New York State Teachers Retirement System’s holdings in Anika Therapeutics were worth $633,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Comerica Bank boosted its position in Anika Therapeutics by 4.9% in the fourth quarter. Comerica Bank now owns 15,834 shares of the biotechnology company’s stock worth $792,000 after buying an additional 739 shares during the period. State Street Corp boosted its position in Anika Therapeutics by 3.2% in the fourth quarter. State Street Corp now owns 316,791 shares of the biotechnology company’s stock worth $15,507,000 after buying an additional 9,917 shares during the period. FMR LLC purchased a new position in Anika Therapeutics during the fourth quarter worth $1,772,000. Thrivent Financial for Lutherans boosted its position in Anika Therapeutics by 5.2% in the fourth quarter. Thrivent Financial for Lutherans now owns 7,920 shares of the biotechnology company’s stock worth $388,000 after buying an additional 390 shares during the period. Finally, New England Research & Management Inc. purchased a new position in Anika Therapeutics during the first quarter worth $447,000. Institutional investors and hedge funds own 81.75% of the company’s stock.
Anika Therapeutics Inc (NASDAQ:ANIK) traded down 0.52% on Friday, hitting $52.00. 105,546 shares of the stock were exchanged. The stock’s 50 day moving average price is $48.17 and its 200 day moving average price is $46.88. The firm has a market cap of $762.22 million, a PE ratio of 23.10 and a beta of 1.69. Anika Therapeutics Inc has a 52-week low of $41.38 and a 52-week high of $52.91.
Anika Therapeutics (NASDAQ:ANIK) last issued its quarterly earnings data on Wednesday, July 26th. The biotechnology company reported $0.76 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.44 by $0.32. The firm had revenue of $33.50 million during the quarter, compared to the consensus estimate of $27.20 million. Anika Therapeutics had a return on equity of 19.23% and a net margin of 33.98%. The company’s quarterly revenue was up 25.9% on a year-over-year basis. During the same period last year, the company earned $0.57 EPS. Equities research analysts forecast that Anika Therapeutics Inc will post $2.00 earnings per share for the current year.
Separately, Zacks Investment Research cut shares of Anika Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, May 8th.
In related news, Director Jeffery S. Thompson sold 10,725 shares of the firm’s stock in a transaction dated Monday, May 22nd. The stock was sold at an average price of $47.39, for a total transaction of $508,257.75. Following the completion of the sale, the director now directly owns 15,845 shares of the company’s stock, valued at approximately $750,894.55. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Charles H. Sherwood sold 63,799 shares of the firm’s stock in a transaction dated Thursday, July 27th. The stock was sold at an average price of $50.79, for a total value of $3,240,351.21. Following the sale, the chief executive officer now directly owns 174,705 shares of the company’s stock, valued at $8,873,266.95. The disclosure for this sale can be found here. Insiders have sold a total of 88,725 shares of company stock valued at $4,459,085 over the last three months. Corporate insiders own 6.57% of the company’s stock.
About Anika Therapeutics
Anika Therapeutics, Inc is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.
Receive News & Ratings for Anika Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.
